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The first year counts: cancer survival
among Indigenous and non-Indigenous
Queenslanders, 1997–2006
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Australians live in remote areas.9
Many remote areas are also characterised by socioeconomic disadvantage,
with both remoteness10,11 and areasocioeconomic disadvantage12 associated with lower cancer survival. Currently, however, there is limited
information on how the Indigenous
survival differential varies across categories of remoteness and area-socioeconomic disadvantage. In this
population-based study, we sought to
address this lack of knowledge, and
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Abstract
Objective: To examine the differential in cancer survival between Indigenous
and non-Indigenous people in Queensland in relation to time after diagnosis,
remoteness and area-socioeconomic disadvantage.
Design, setting and participants: Descriptive study of population-based data
on all 150 059 Queensland residents of known Indigenous status aged 15 years
and over who were diagnosed with a primary invasive cancer during 1997–2006.
Main outcome measures: Hazard ratios for the categories of areasocioeconomic disadvantage, remoteness and Indigenous status, as well as
conditional 5-year survival estimates.
Results: Five-year survival was lower for Indigenous people diagnosed with
cancer (50.3%; 95% CI, 47.8%–52.8%) compared with non-Indigenous people
(61.9%; 95% CI, 61.7%–62.2%). There was no evidence that this differential
varied by remoteness (P = 0.780) or area-socioeconomic disadvantage
(P = 0.845). However, it did vary by time after diagnosis. In a time-varying
survival model stratified by age, sex and cancer type, the 50% excess mortality
in the first year (adjusted HR, 1.50; 95% CI, 1.38–1.63) reduced to near unity
at 2 years after diagnosis (HR, 1.03; 95% CI, 0.78–1.35).
Conclusions: After a wide disparity in cancer survival in the first 2 years
after diagnosis, Indigenous patients with cancer who survive these 2 years
have a similar outlook to non-Indigenous patients. Access to services and
socioeconomic factors are unlikely to be the main causes of the early lower
Indigenous survival, as patterns were similar across remoteness and areasocioeconomic disadvantage. There is an urgent need to identify the factors
leading to poor outcomes early after diagnosis among Indigenous people
with cancer.

thus inform further research, policy
and clinical priorities aimed at
redressing the survival inequalities
currently experienced by Indigenous
people with cancer.

Methods
Data were provided by the population-based Queensland Cancer Registry (QCR),13 under an agreement
between Cancer Council Queensland
and Queensland Health allowing
access to non-identifiable data. For
these analyses, all people of known
Indigenous status aged 15 years and
over who were diagnosed with a primary invasive cancer (International
classification of diseases for oncology,
3rd edition [ICD-O-3] codes, C00–
C80) during 1 January 1997 to 31
December 2006 were included. We
excluded people whose age or residential location at diagnosis was
unknown, or whose diagnosis was

based on the death certificate or
autopsy report only. Cases included in
the study were followed to 31 December 2007, with matching to the
National Death Index. Those still alive
at 31 December 2007 were censored
at that date, while those who died
from a cause other than the diagnosed
cancer were censored at their date of
death.
Cancer type

Since the differential in the incidence
of cancer between Indigenous and
non-Indigenous depends on cancer
type, with cancers common among
Indigenous people more likely to be
associated with low survival rates,14
we constructed a variable representing broad cancer groups based on 5year cancer survival estimates for all of
Queensland13 to include in the analysis. These estimates were: < 25% (eg,
cancers of the oesophagus, liver, lung,
pancreas and unknown site); 25%–
49% (eg, stomach and ovarian can-

Research

Residential location at diagnosis was
obtained from the QCR, according to
Statistical Local Area (SLA). These
SLAs were then grouped according to
the level of geographic remoteness
based on the Accessibility/Remoteness Index of Australia (ARIA+).
Area-level socioeconomic disadvantage was measured by quintiles of the
Index of Relative Socioeconomic
A dv a n t a g e a n d D i s a d v a n t a g e
(IRSAD), because this index is determined without including Indigenous
status.15
Demographics

Information on sex, age at diagnosis
and Indigenous status was obtained
from the QCR. Age at diagnosis was
categorised into five age groups (15–
49, 50–59, 60–69, 70–79 and 80 +
years). The QCR obtains information
about Indigenous status of cancer
patients through the process of cancer
notification from Queensland hospitals. Ascertainment of Indigenous status is bas ed on an in dividual
identifying him- or herself as either
Aboriginal only, Aboriginal and Torres
Strait Islander or Torres Strait Islander
only. As the focus of our analysis was
on the survival differential between
Indigenous and non-Indigenous people, we also excluded those patients
whose ethnicity was unknown.
Statistical methods

Cox proportional hazards regression
models were used to quantify the survival differences with Efron’s approximation used to resolve tied data (ie,
multiple deaths at the same number
of days from diagnosis).16 Data were
analysed with Stata, version 11.0
(StataCorp, College Station, Tex,
USA).
Variables considered for inclusion
in the model were geographic
remoteness, area-socioeconomic disadvantage, age group, sex, Indigenous
status, and broad cancer group. Cancer stage could not be included
because the QCR does not routinely
collect these data at diagnosis. Inter-

Cases of invasive cancer diagnosed in people aged ≥ 15 years in Queensland, 1997-2006
180 095

Unknown ethnicity
26 294 (14.6%)

Other exclusions†
4502 (2.5%)

Complete information*
150 059 (83.3%)

Indigenous patients
1819 (1.2%)

Non-Indigenous patients
148 240 (98.8%)

ARIA+ = Accessibility/Remoteness Index of Australia. IRSAD = Index of Relative Socioeconomic Advantage and Disadvantage.
* Includes ethnicity, ARIA+, IRSAD and dates at death and/or diagnosis. † Includes diagnosis by death certiﬁcate or at autopsy,
and missing information.
◆

actions between covariates, including
time-varying coefficients, were also
considered.
A systematic process was used to
develop the final model, considering
the proportional hazards assumption,
overall model fit and the influence
exerted by individual cases. Scaled
Schoenfeld residuals, which test for
non-zero slope over time, were used
to check if the proportional hazards
assumptions were satisfied. Model
goodness of fit was assessed by Cox–
Snell residuals. Deviance residuals
were then used to examine model
accuracy. We considered the influence
of individual cases to determine their
impact on each of the estimated individual coefficients (using the DFBETA
statistic) as well as their effect on the
combined set of coefficients (using
the LMAX statistic).16,17
Conditional survival, which reflects
the average probability of an individual
surviving a certain number of years
given they have already survived for x
years,18 was calculated for both Indigenous and non-Indigenous cohorts.

Results
Of the original 180 095 people aged 15
years and over who were diagnosed
with invasive cancer in Queensland
between 1997 and 2006, 14.6% were
of unknown ethnicity (Box 1). A further 2.5% were excluded because they
were either diagnosed at death (total,
1.5%; Indigenous, 2.9%; non-Indigenous, 1.5%), did not have information
on the SLA of residence (total, 0.8%;
Indigenous, 0.7%; non-Indigenous,
0.8%) or the number of days between
diagnosis and death (total, 0.2%;
Indigenous, 0.3%; non-Indigenous,
0.2%), or did not have a SEIFA value
assigned (total, 0; Indigenous, 0.4%;

2 Comparison of survival between Indigenous and nonIndigenous people aged ⭓ 15 years diagnosed with invasive
cancers in Queensland, 1997–2006

A: Kaplan–Meier survival curve at diagnosis
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1 Flow chart illustrating case ascertainment for the study
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Number at risk
Non−Indigenous 148 240
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B: Kaplan–Meier survival curve 2 years after diagnosis
1.0
Proportion surviving

cers, myeloid leukaemia, myeloma);
50%–74% (eg, colorectal and kidney
cancers, non-Hodgkin lymphoma)
and 75%–100% (eg, breast, cervical
and prostate cancers and melanoma).
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0.8
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non-Indigenous, 0). The final cohort
included 150 059 individuals of
known ethnicity, of whom 1819
(1.2%) were Indigenous (Box 1). The
most common cancers among Indigenous people were lung, breast, colorectal, prostate and cervical cancers.
Among non-Indigenous people, the
most common cancers were colorectal, breast, prostate and lung cancers
and melanoma. A slight majority
(55.5%) of people diagnosed with
cancers were males.
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3 Cause-specific survival estimates and Cox proportional hazard ratios for all people aged ⭓ 15 years
diagnosed with invasive cancers in Queensland, 1997–2006
No. at
start

5-year survival
estimate* (95% CI)

Hazard ratio
(95% CI)

P†
< 0.001

ARIA+
Major city

87 569

63.2% (62.8%–63.5%)

1.00

Inner regional

33 520

62.2% (61.6%–62.7%)

1.05 (1.02–1.07)

Outer regional

22 516

57.8% (57.1%–58.5%)

1.17 (1.14–1.20)

Remote/very remote

6 454

54.9% (53.6%–56.3%)

1.24 (1.19–1.29)

20 737

66.1% (65.4%–66.8%)

1.00

Advantaged

34 638

63.7% (63.1%–64.3%)

1.02 (0.99–1.05)

Middle socioeconomic status

39 805

61.3% (60.8%–61.8%)

1.09 (1.05–1.12)

< 0.001

IRSAD
Most advantaged

Disadvantaged

34 510

59.9% (59.3%–60.4%)

1.11 (1.07–1.14)

Most disadvantaged

20 369

58.3% (57.6%–59.1%)

1.10 (1.06–1.14)

21 331

78.7% (78.1%–79.3%)

Age groups
15–49 years

‡

69.0% (68.4%–69.6%)

50–59 years

26 349

60–69 years

36 637

63.2% (62.7%–63.8%)

70–79 years

40 952

56.0% (55.4%–56.5%)

⭓ 80 years

24 790

44.6% (43.8%–45.3%)

Males

83 278

58.9% (58.5%–59.3%)

Females

66 781

65.3% (64.9%–65.7%)

Sex
‡

Broad cancer site groups
Very low survival
Low survival
Medium survival
High survival

30 519

15.4% (14.9%–15.8%)

11 144

39.9% (38.8%–41.0%)

39 410

64.2% (63.6%–64.7%)

68 986

84.0% (83.7%–84.3%)

148 240

61.9% (61.7%–62.2%)

1 819

50.3% (47.8%–52.8%)

‡

Indigenous status
Non-Indigenous
Indigenous

§

Risk of death among Indigenous compared with non-Indigenous people§

< 0.001

0–1 years after diagnosis

1.50 (1.38–1.63)

The final multivariate model

1–2 years after diagnosis

1.20 (1.01–1.42)

2–3 years after diagnosis

1.03 (0.78–1.35)

The final model included rurality
(ARIA+), area-socioeconomic disadvantage (IRSAD), Indigenous status
and time-varying Indigenous components, and was stratified by broad
cancer site category, sex and age
group. The graph of Cox–Snell residuals (not shown) indicated excellent
model fit, and there was no evidence
the parameter estimates were being
overly influenced by outlying individual datapoints.
Survival estimates and results from
the final Cox hazard model are shown
in Box 3. Indigenous people experienced poorer survival during the first
and second years after diagnosis after
stratifying by age, sex and broad cancer site category, and adjusting for
area-level disadvantage and remoteness. This disparity decreased with
time since diagnosis, and after 2 years
there was no survival disparity
between Indigenous and non-Indigenous patients with cancer.

3–4 years after diagnosis

1.24 (0.87–1.75)

4–5 years after diagnosis

0.48 (0.24–0.97)

⭓ 5 years after diagnosis

0.65 (0.39–1.08)

ARIA+ = Accessibility/Remoteness Index of Australia. IRSAD = Index of Relative Socioeconomic Advantage and Disadvantage.
* Calculated using Stata statistical software’s ltable command, and has not been adjusted for other variables in the model.
† Calculated using the likelihood ratio test. ‡ Due to non-proportional hazards, the model was stratiﬁed by broad cancer site, sex
and age group, so hazard ratios were not estimated. § Interaction terms were included in the model because the Indigenous
differential varied according to time after diagnosis.
◆

Bivariate comparisons of survival

There was clear evidence of lower cancer survival for Indigenous compared
with non-Indigenous people (Box 2A).
The survival curves in Box 2A show the
cumulative survival from diagnosis.
Unadjusted survival curves by
remoteness suggested lower survival
for Indigenous people in outer regional
and remote areas, but not in more
urban areas (results not shown). The
interpretation of survival curves by area
disadvantage was difficult because of
the small numbers of Indigenous
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proportional hazards assumptions
were clearly not met for each broad
cancer group (based on scaled
Schoenfeld residuals, each P < 0.001),
so the model was adjusted to include
cancer site as a stratification variable.
The plot of the hazard function by
Indigenous status (not shown)
revealed large initial differences in
hazards, which decreased over time
since diagnosis. After surviving 2
years, there was no difference in
unadjusted cumulative survival by
Indigenous status (Box 2B). Therefore, time-varying components
(Indigenous status by follow-up years
after diagnosis) were incorporated
into the model. To prevent a few cases
with longer follow-up exerting undue
influence on survival estimates, time
since diagnosis was categorised up to
5 + years of follow-up.
Proportional hazards assumptions
were not being met for the final age
category (P < 0.001) or sex (P < 0.001).
While including the interaction terms
Indigenous–sex and Indigenous–age
group improved the model fit based
on the likelihood-ratio tests, the proportional hazards assumptions were
s t i l l v i o l a te d (o v e r a l l m o d e l ,
P < 0.001). To address this, we further
included age and sex in the model as
stratification variables.
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patients in more affluent areas. Nonetheless, differences in survival were not
apparent until we looked at the disadvantaged and most disadvantaged
quintiles, where Indigenous cancer
patients had poorer survival than nonIndigenous patients.
Development of multivariate model

The initial model included all variables in the model (age group, sex,
rurality, area-socioeconomic disadvantage, broad category of cancer site
and Indigenous status). However,

Research
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Conditional 5-year survival estimates* by number of years after diagnosis for all
invasive cancers diagnosed in patients aged 15 years and over in Queensland,
1997–2006
5-year survival (95% CI)

Years after diagnosis

Indigenous

Non-Indigenous

0 (at diagnosis)

50.3% (47.8%–52.8%)

61.9% (61.7%–62.2%)

1

74.3% (70.5%–78.1%)

76.8% (76.5%–77.2%)

2

83.7% (84.8%–91.9%)

83.0% (82.7%–83.4%)

3

88.3% (84.8%–91.9%)

86.5% (86.1%–86.9%)

4

92.6% (89.0%–96.2%)

88.7% (88.3%–89.1%)

5

94.3% (91.0%–97.5%)

90.4% (89.9%–90.8%)

* Survival calculated by the cohort method for cause-specific survival, 1997–2006, with follow-up to
31 December 2007. Estimates refer to the percentage of patients surviving an additional 5 years at the
specified number of years after the original cancer diagnosis, and have not been adjusted for factors
such as age, sex or type of cancer.
◆

Survival was lower for people living
in less accessible areas and those in
more disadvantaged areas. However,
there was no significant evidence for
interaction found between Indigenous
status and either remoteness (P =
0.780) or area disadvantage (P = 0.845).
Two sensitivity analyses were conducted. The first included patients of
unknown Indigenous status in the
non-Indigenous group, while the second included those diagnosed at
death (by death certificate or autopsy)
by assuming they survived for 1 year.
In both cases, the analyses yielded
similar results, with hazard ratios
slightly higher when including those
of unknown Indigenous status.
Conditional survival

Conditional survival estimates (Box 4)
reinforce the time-dependent nature
of the differential in survival between
Indigenous and non-Indigenous
patients with cancer. Indigenous
patients initially had poorer 5-year
survival prognoses than non-Indigenous patients, but this disparity in
survival expectations vanished once
they had survived 2 or more years.

Discussion
In this population-based study of
cancer in Queensland, we found significant disparities between the survival outcomes for Indigenous and
non-Indigenous people after their
di agnosi s. Th ese di ffere nc es
remain ed after accoun ting fo r
remoteness, area-socioeconomic disadvantage, age group, sex and mix of
cancers. However, this survival disparity was modified by time since

diagnosis, with the comparative risk
of death decreasing as the time from
diagnosis increased. This varying
time effect has not been previously
noted in studies examining cancer
survival among Indigenous people in
Australia,4,19 apart from a brief mention of time-varying comparative
Indigenous and non-Indigenous survival in patients with colorectal cancer in the Northern Territory.20
This is important information for
Indigenous patients with cancer to
know, because the longer they survive
the greater chance they have of continuing to survive. Most of the currently published literature has focused
on the poorer survival outcomes of
Australian Indigenous people diagnosed with cancer. This is justifiable,
and has helped galvanise a concerted
government, clinical and research
effort to reduce this disparity in cancer
survival. However, the perspective
that Indigenous cancer patients have
a continued poorer prognosis cannot
help but limit their own personal
optimism and outlook for the future.
Thus, our results, based on the total
Queensland population, provide an
avenue for increased optimism among
Indigenous cancer patients that they
can successfully complete their cancer
journey.
However, this optimism must be
constrained by a strong call to action
to understand what is causing the
very wide disparity in survival within
the first 1 to 2 years after diagnosis. A
recent Queensland study showed a
survival differential for Indigenous
patients with breast cancer that
remained even after adjusting for
spread of disease.21 This suggests that

other factors, such as the impact of
poorer general health and increased
comorbid conditions among the
Indigenous compared with the nonIndigenous population, also play an
important role. There may be a
healthy cohort effect, as Indigenous
patients who survive beyond 2 years
after diagnosis may have fewer
comorbid conditions or better general
health than those who died earlier.
Alternatively, Indigenous patients
with cancer in Queensland (all cancers) are less likely to undergo treatment for their cancer than other
patients.8 Indigenous patients who
use health services and receive adequate treatment may have better rates
of survival.22 Until Australian cancer
registries standardise the collection
and recording of stage and treatment
data, it will be impossible to explore
these factors appropriately.
We found no evidence that the differential in Indigenous versus nonIndigenous survival varied according
to geographical area of residence. As
the use of any area-based measure of
socioeconomic status is likely to overestimate the affluence of Indigenous
people,23 this reinforces the lack of
evidence. This may indicate the Indigenous survival differential is not primarily related to access to treatment
or socioeconomic barriers, but that
other as yet unknown factors are
more relevant, including those related
to culture and general health, and that
these other factors have similar
impact across geographical locations.
Clearly, having an almost 50% differential in cancer survival within the
first 12 months of diagnosis is not
acceptable, and our findings should
increase the motivation for further
efforts in this area. Greater emphasis
and research focus should therefore
be placed on identifying the factors
responsible for the early disparity in
survival.
Limitations of our study include the
relatively small numbers of Indigenous cases, which gave us limited
capacity to investigate differences for
specific types of cancer. We were also
unable to separate the effects of early
diagnosis from other factors, including
those of treatment differentials. As it is
possible that not all cases of cancer in
Indigenous people were identified,
there is potential misclassification of
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true Indigenous status. However, this
misclassification is thought to be
small,8 and ascertainment is considered high.2
In conclusion, our findings provide
some cause for cautious optimism, as
Indigenous patients in Queensland
who have already survived 2 years
after a cancer diagnosis are likely to
have a similar outlook to that of nonIndigenous patients. However, there
is still an urgent need to address the
unacceptable disparity in survival outcomes early after diagnosis. This
important health issue must remain a
continuing priority.
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